AIM: To examine the prevalence and prognostic significance of C-kit gene mutation and analysis the correlation of C-kit gene mutation and the clinicalpathologic parameters of GISTs. METHODS: Eighty-two GISTs were studied for the mutation of C-kit gene by PCR-SSCP, DNA sequence. Statistical comparison were used to analysis the correlation of C-kit gene mutation and clinicalpathology, clinical behavior, recurrence. RESULTS: (1) Mutation-positive and mutation-negative GISTs were 34 and 48,respectively; (2) Among these patients with C-kit mutation remained a significantly poor prognosis associated with 59% 3-year survival compared to those whose tumors did not; (3) Tumor size, PCNA index, mitotic cell number, presence of necrosis, microscopic invasion to adjacent tissues, recurrence and distant metastasis among mutation-positive and mutation-negative GISTs were significantly different. CONCLUSION: C-kit mutation is a undoubtedly pivotal event in GIST and may be associated with poor prognosis. Evaluation of C-kit gene mutation may have both prognosis and therapeutic significances.
AIM: To examine the prevalence and prognostic significance of C-kit gene mutation and analysis the correlation of C-kit gene mutation and the clinicalpathologic parameters of GISTs. METHODS: Eighty-two GISTs were studied for the mutation of C-kit gene by PCR-SSCP, DNA sequence. Statistical comparison were used to analysis the correlation of C-kit gene mutation and clinicalpathology, clinical behavior, recurrence. RESULTS: (1) Mutation-positive and mutation-negative GISTs were 34 and 48,respectively; (2) Among these patients with C-kit mutation remained a significantly poor prognosis associated with 59% 3-year survival compared to those whose tumors did not; (3) Tumor size, PCNA index, mitotic cell number, presence of necrosis, microscopic invasion to adjacent tissues, recurrence and distant metastasis among mutation-positive and mutation-negative GISTs were significantly different. CONCLUSION:C-kit mutation is a undoubtedly pivotal event in GIST and may be associated with poor prognosis. Evaluation of C-kit gene mutation may have both prognosis and therapeutic significances.
Authors: H Joensuu; P J Roberts; M Sarlomo-Rikala; L C Andersson; P Tervahartiala; D Tuveson; S Silberman; R Capdeville; S Dimitrijevic; B Druker; G D Demetri Journal: N Engl J Med Date: 2001-04-05 Impact factor: 91.245
Authors: R Fukuda; N Hamamoto; Y Uchida; K Furuta; T Katsube; H Kazumori; S Ishihara; K Amano; K Adachi; M Watanabe; Y Kinoshita Journal: Intern Med Date: 2001-04 Impact factor: 1.271
Authors: N A C S Wong; R Young; R D G Malcomson; A G Nayar; L A Jamieson; V E Save; F A Carey; D H Brewster; C Han; A Al-Nafussi Journal: Histopathology Date: 2003-08 Impact factor: 5.087
Authors: Min Ki Kim; Jae Kyung Lee; Eun Taek Park; Sang Hyuk Lee; Sang Young Seol; Jung Myung Chung; Mi Seon Kang; Hye Kyoung Yoon Journal: Korean J Gastroenterol Date: 2004-06
Authors: Animesh Pardanani; Terra L Reeder; Teresa K Kimlinger; Jin Y Baek; Chin-Y Li; Joseph H Butterfield; Ayalew Tefferi Journal: Leuk Res Date: 2003-08 Impact factor: 3.156
Authors: Chun-Meng Wang; Kai Huang; Ye Zhou; Chun-Yan Du; Yan-Wei Ye; Hong Fu; Xiao-Yan Zhou; Ying-Qiang Shi Journal: J Cancer Res Clin Oncol Date: 2009-12-31 Impact factor: 4.553
Authors: Jason S Gold; Mithat Gönen; Antonio Gutiérrez; Javier Martín Broto; Xavier García-del-Muro; Thomas C Smyrk; Robert G Maki; Samuel Singer; Murray F Brennan; Cristina R Antonescu; John H Donohue; Ronald P DeMatteo Journal: Lancet Oncol Date: 2009-09-28 Impact factor: 41.316
Authors: Antonio Chiappa; Andrew P Zbar; Michael Innis; Stuart Garriques; Emilio Bertani; Roberto Biffi; Giancarlo Pruneri; Felipe Luzzato; Paolo Della Vigna; Cristina Trovato; Bruno Andreoni Journal: World J Surg Oncol Date: 2006-10-09 Impact factor: 2.754